Last reviewed · How we verify
Approved COVID-19 vaccine
This vaccine works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body build immunity against COVID-19.
This vaccine works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body build immunity against COVID-19. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
At a glance
| Generic name | Approved COVID-19 vaccine |
|---|---|
| Sponsor | Humanity & Health Medical Group Limited |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
The vaccine uses a piece of the virus's genetic material, specifically the spike protein, to stimulate the body's immune system to produce antibodies and immune cells that can recognize and fight the virus. This immune response helps protect against severe illness and death from COVID-19.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Chills
Key clinical trials
- Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- COVID-19 Vaccination of Immunodeficient Persons (COVAXID) (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age (PHASE3)
- Korea Comirnaty Post-marketing Surveillance
- Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults (PHASE2)
- A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection (PHASE2)
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Approved COVID-19 vaccine CI brief — competitive landscape report
- Approved COVID-19 vaccine updates RSS · CI watch RSS
- Humanity & Health Medical Group Limited portfolio CI